Drug interaction between

##plugins.themes.academic_pro.article.main##

Emna Gaies
Fatma Zgolli
Rim Charfi
Mouna Ben Sassi
Hanene El Jebari
Issam Salouage
Riadh Daghfous
Sameh Trabelsi

Abstract

Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account.
Aim: To assess the influence of the coadministration of CBZ with other AED on the trough plasmatic concentration (C0) of CBZ in epileptic adults.
Methods: We performed a retrospective study over a period of 9 years in the Department of Clinical Pharmacology in the Tunisian National Centre “Chalbi Belkahia” of Pharmacovigilance. Our study included samples from adult patients receiving CBZ alone or associated to other AED for epilepsy. Trough plasma CBZ plasma concentrations were measured by an immunological method. Included samples were divided in four groups: i/ group 1 (G1) receiving CBZ as monotherapy, ii/ group 2 (G2) treated by CBZ with an enzyme inducer (phenobarbital or phenytoin), iii/ group 3 (G3) taking CBZ associated to an enzyme inhibitor (valproic acid (VPA)), iv/ group 4 (G4), treated by CBZ associated to enzyme inducer (phenobarbital or phenytoin) and enzyme inhibitor (valproic acid) at the same time.
Results: There were no significant differences between different groups in age, weight and sex ratio. However statistical analysis showed a significant decrease in C0/D CBZ ratio between G1 and G2 and between G1 and G4 (p<0.001). However, the difference was not significant between G1 and G3 (p=1.2044).
Conclusion: It is important to check and to prevent the consequences of the interaction between CBZ and other AED in order to avoid inefficiency and toxicity.

Keywords:

carbamazepine, drug interactions, antiepileptic drugs, antiepileptic adults, epilepsy

##plugins.themes.academic_pro.article.details##

References

  1. • Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409- 32. • Bosaka M, Słowika A, Iwańskab A, Lipińskab M, Turaja W. Co-medication and potential drug interactions among patients with epilepsy. Seizure: European Journal of Epilepsy. 2019;66:47-52 • Puranik YG, Birnbaum AK, Marino SE, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013;14(1):35-45. • Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007; 76(3):391-6. • Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013;18(Suppl 1):S81-S85. • Liu H, Delgado MR, Browne RH. Interaction of valproic acid with carbamazepine and its metabolites concentrations, concentrations ratios, and level/dose ratios in epileptic children. ClinNeuropharmacol.1995; 8:1-12 • Marvanova M. Pharmacokinetic characteristics of antiepileptic drugs. Ment Health Clin. 2016;6(1):8-20.